Balyasny Asset Management
MYGN icon

Balyasny Asset Management’s Myriad Genetics MYGN Stock Holding History

Balyasny Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-624,000
Closed -$14.5M – 2562
2023
Q2 		$14.5M Buy
624,000
+72,400
+13% +$1.58M 0.03% 642
2023
Q1 		$12.8M Buy
+551,600
New +$11.2M 0.03% 683
2014
Q2 		– Sell
-50,000
Closed -$1.71M – 727
2014
Q1 		$1.71M Buy
+50,000
New +$1.55M 0.02% 482
2013
Q4 		– Sell
-11,428,400
Closed -$24M – 584
2013
Q3 		$24M Buy
+11,428,400
New +$325M 0.32% 69

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's MYGN Position: Q1 2026 in Review

Balyasny Asset Management sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 16,155 shares — an estimated $99.4K sold.

Balyasny Asset Management first reported a position in MYGN in Q4 2016 and held it in 20 quarters. The position peaked at $36.9M in Q1 2023. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Balyasny Asset Management reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 16,155 Myriad Genetics shares in Q1 2026, an estimated $99.4K.
  • Balyasny Asset Management first reported a position in Myriad Genetics in Q4 2016 and held it in 20 quarters.
  • Balyasny Asset Management's Myriad Genetics position peaked at $36.9M in Q1 2023.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.